Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NBTX Nanobiotix	$9.70 +13.7%	$5.93	$2.76 ▼ $9.80	$465.02M	0.45	11,702 shs	35,251 shs
OLMA Olema Pharmaceuticals	$5.54 +1.7%	$4.72	$2.86 ▼ $13.93	$380.21M	1.92	872,479 shs	398,691 shs
VIGL Vigil Neuroscience	$8.05	$8.01	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A
XBIT XBiotech	$3.20 -0.6%	$2.92	$2.50 ▼ $8.32	$97.57M	0.97	67,500 shs	44,068 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NBTX Nanobiotix	-5.22%	+7.11%	+66.93%	+127.47%	+78.83%
OLMA Olema Pharmaceuticals	+0.37%	+3.12%	+18.74%	+5.62%	-55.58%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.37%	+2.16%	+126.12%
XBIT XBiotech	+0.31%	+2.55%	+9.15%	+13.38%	-48.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NBTX Nanobiotix	0.7208 of 5 stars	1.3	3.0	2.5	0.0	0.6
OLMA Olema Pharmaceuticals	1.8146 of 5 stars	3.3	0.0	3.0	2.5	0.0
VIGL Vigil Neuroscience	1.8915 of 5 stars	3.0	3.0	0.0	2.5	0.6
XBIT XBiotech	1.7207 of 5 stars	0.0	4.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	-17.53% Downside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	333.21% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside
XBIT XBiotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, VIGL, NBTX, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NBTX Nanobiotix	$39.18M	11.87	N/A	N/A	($1.51) per share	-6.42
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A
XBIT XBiotech	$4.01M	24.33	N/A	N/A	$5.68 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	N/A
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	11/6/2025 (Estimated)
XBIT XBiotech	-$38.53M	-$0.92	N/A	∞	N/A	N/A	-15.60%	-14.64%	N/A

Latest XBIT, VIGL, NBTX, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	XBIT XBiotech	N/A	-$0.06	N/A	-$0.06	N/A	N/A
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NBTX Nanobiotix	N/A	1.04	1.04
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
VIGL Vigil Neuroscience	N/A	2.97	2.97
XBIT XBiotech	N/A	40.16	40.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NBTX Nanobiotix	38.81%
OLMA Olema Pharmaceuticals	91.78%
VIGL Vigil Neuroscience	83.64%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
NBTX Nanobiotix	3.45%
OLMA Olema Pharmaceuticals	16.36%
VIGL Vigil Neuroscience	18.01%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

XBIT, VIGL, NBTX, and OLMA Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Releases Quarterly Earnings Results

August 16, 2025 | marketbeat.com

XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 452.0% in July

August 2, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

August 1, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Shares Cross Below 50 Day Moving Average - Should You Sell?

July 23, 2025 | marketbeat.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 14, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 13, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, VIGL, NBTX, and OLMA Company Descriptions

Nanobiotix NASDAQ:NBTX

$9.70 +1.17 (+13.72%)

Closing price 03:57 PM Eastern

Extended Trading

$9.62 -0.07 (-0.77%)

As of 04:57 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Olema Pharmaceuticals NASDAQ:OLMA

$5.54 +0.09 (+1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$5.54 +0.00 (+0.09%)

As of 04:20 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

XBiotech NASDAQ:XBIT

$3.20 -0.02 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 -0.01 (-0.16%)

As of 04:10 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time